World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
129
Citations
70638
World Ranking
2566
National Ranking
1440

Overview

Srdan Verstovsek is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medical studies within the field of medicine, with a particular emphasis on genetics and hematology. The subfields in which they have contributed significantly include genetics, hematology, molecular biology, rheumatology, and oncology.

The main topics covered in their work are diverse and span several areas related to blood disorders and cancer treatment. These topics include:

  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Acute Myeloid Leukemia Research
  • Eosinophilic Disorders and Syndromes
  • Kruppel-like factors research
  • Multiple Myeloma Research and Treatments
  • Hemoglobinopathies and Related Disorders

Srdan Verstovsek has published extensively in well-known scientific journals. Frequent publication venues include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • HemaSphere
  • Journal of Clinical Oncology
  • Blood Advances

Some of the recent papers authored or co-authored by Verstovsek include:

  • "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms," 2022, Leukemia
  • "10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial," 2020, The Lancet Haematology
  • "Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study," 2023, The Lancet
  • "Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study," 2020, The Lancet Haematology
  • "Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure," 2020, American Journal of Hematology

The scientist frequently collaborates with other researchers in the field. Key co-authors include:

  • Ruben A. Mesa
  • Claire Harrison
  • Jean-Jacques Kiladjian
  • Naveen Pemmaraju
  • Prithviraj Bose

Best Publications

  • A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

    Srdan Verstovsek;Ruben A. Mesa;Jason Gotlib;Richard S. Levy

  • Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

    Srdan Verstovsek;Hagop Kantarjian;Ruben A. Mesa;Animesh D. Pardanani

  • Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

    Alfonso Quintás-Cardama;Kris Vaddi;Phillip Liu;Taghi Manshouri

  • Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

    Tiziano Barbui;Giovanni Barosi;Gunnar Birgegard;Francisco Cervantes

  • Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

    Alessandro M. Vannucchi;Jean Jacques Kiladjian;Martin Griesshammer;Tamas Masszi

  • Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

    Ayalew Tefferi;Juergen Thiele;Attilio Orazi;Hans Michael Kvasnicka

  • Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

    Deborah A. Thomas;Stefan Faderl;Jorge Cortes;Susan O'Brien

  • Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

    Deborah A. Thomas;Stefan Faderl;Susan O'Brien;Carlos Bueso-Ramos

  • Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

    Guillermo Garcia-Manero;Hagop M. Kantarjian;Blanca Sanchez-Gonzalez;Hui Yang

  • High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia

    Hagop Kantarjian;Moshe Talpaz;Susan O'Brien;Guillermo Garcia-Manero

  • Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet

    Tiziano Barbui;Ayalew Tefferi;Alessandro M. Vannucchi;Francesco Passamonti

  • JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemia

    Jaroslav Jelinek;Yasuhiro Oki;Vazganush Gharibyan;Vazganush Gharibyan;Vazganush Gharibyan;Carlos Bueso-Ramos

  • Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

    Deborah A. Thomas;Susan O'Brien;Stefan Faderl;Guillermo Garcia-Manero

  • Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

    E. Jabbour;H. Kantarjian;D. Jones;M. Talpaz

  • The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

    Ruben A. Mesa;Joyce Niblack;Martha Wadleigh;Srdan Verstovsek

  • Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

    Alfonso Quintás-Cardama;Hagop Kantarjian;Taghi Manshouri;Rajyalakshmi Luthra

  • Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

    Elihu Estey;Guillermo Garcia-Manero;Alessandra Ferrajoli;Stefan Faderl

  • Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

    Farhad Ravandi;Eli Estey;Dan Jones;Stefan Faderl

  • Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

    G. Barosi;R. A. Mesa;J. Thiele;F. Cervantes

  • Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.

    Hagop M Kantarjian;Varsha Gandhi;Jorge Cortes;Srdan Verstovsek

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias Jabbour The University of Texas MD Anderson Cancer Center
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center
Sherry Pierce
Sherry Pierce The University of Texas MD Anderson Cancer Center
Ruben A. Mesa
Ruben A. Mesa The University of Texas Health Science Center at San Antonio

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare education and career options is a smart choice for those interested in Medicine, but looking for flexible or accelerated pathways. Online programs have made it easier to access high-quality education in related fields like nursing and medical administration.

For example, entry level msn programs online allow individuals without a nursing background to pursue a master’s degree and quickly transition into advanced practice roles. Additionally, those wanting a more accessible route can consider easy nursing programs to get into, which offer less competitive admissions processes.

Not everyone seeking a healthcare career wants to work directly with patients. Careers in medical billing and coding are in high demand and offer flexibility, with many students asking, can you get financial aid for medical billing and coding? The answer is often yes, making this pathway more accessible.

For prospective nurses worried about entrance exams, there are also lpn program no entrance exam options. These programs help streamline entry into the nursing field, making it easier to start a rewarding healthcare career.

Best Scientists Citing Srdan Verstovsek

Trending Scientists

Recently Published Articles